Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · IEX Real-Time Price · USD
4.690
+0.010 (0.21%)
At close: Jul 19, 2024, 4:00 PM
4.610
-0.080 (-1.71%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $27.10M in the twelve months ending March 31, 2024, with 389.30% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $4.91M with 64.29% year-over-year growth. In the year 2023, Capricor Therapeutics had annual revenue of $25.18M with 886.81% growth.
Revenue (ttm)
$27.10M
Revenue Growth
+389.30%
P/S Ratio
5.53
Revenue / Employee
$265,669
Employees
102
Market Cap
149.98M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
Dec 31, 2013 | 503.23K | -1.40M | -73.50% |
Dec 31, 2012 | 1.90M | 544.26K | 40.18% |
Dec 31, 2011 | 1.35M | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 101.40K | -279.44K | -73.37% |
Dec 31, 2006 | 380.84K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 503.78M |
Quipt Home Medical | 185.39M |
Lifecore Biomedical | 103.27M |
OptiNose | 74.02M |
ProQR Therapeutics | 14.66M |
Vaxart | 8.89M |
CAPR News
- 26 days ago - CORRECTION: Capricor Therapeutics - GlobeNewsWire
- 26 days ago - Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway - GlobeNewsWire
- 5 weeks ago - Capricor Advances in DMD Therapy With Positive Study Data - Benzinga
- 2 months ago - Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting - GlobeNewsWire
- 2 months ago - Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences - GlobeNewsWire
- 2 months ago - Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13 - GlobeNewsWire